Maxcyte, Inc.
MXCT- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001287098
No open-market purchases or sales by Maxcyte, Inc. insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $78.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Maxcyte, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Maxcyte, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Douglas Richard | Director | 260,998 | Jun 22, 2026 | 1 |
| Balthrop Patrick J | Director | 80,998 | Jun 22, 2026 | 1 |
| Erck Stanley C | Director | 428,749 | Jun 22, 2026 | 1 |
| Collins Cynthia | Director | 111,310 | Jun 22, 2026 | 1 |
| Brooke William W | Director | 181,300 | Jun 22, 2026 | 1 |
| Al-Wakeel Yasir B. | Director | 80,998 | Jun 22, 2026 | 1 |
| Hemrajani Rekha | Director | 70,314 | Jun 22, 2026 | 1 |
| Johnston John Joseph | Director | 201,581 | Jun 22, 2026 | 1 |
| Ahuja Parmeet | Chief Financial Officer | 187,500 | Apr 17, 2026 | 2 |
| Masoud Maher | President and CEO | 475,000 | Mar 31, 2026 | 1 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER | 151,669 | Mar 19, 2026 | 1 |
| Sandoval David I. | GENERAL COUNSEL | 64,219 | Mar 20, 2025 | 0 |
| Soleymannezhad Ali | Chief Commercial Officer | 59,439 | Mar 20, 2025 | 0 |
| Ross Thomas M. | EVP, GLOBAL SALES | 25,000 | Aug 5, 2024 | 0 |
| Mandell Art | Director | 395,851 | Jun 13, 2024 | 0 |
| Doerfler Douglas | President and CEO | 333,197 | Dec 6, 2023 | 0 |
| Holtz Ron | Chief Financial Officer | 125,251 | Mar 21, 2023 | 0 |
| Sumen Cenk | Chief Scientific Officer | – | Mar 21, 2023 | 0 |
| Casdin Partners GP, LLC | 10% Owner | 10,000,000 | Oct 5, 2022 | 0 |
| Casdin Capital, LLC | 10% Owner | 10,000,000 | Oct 5, 2022 | 0 |
| Casdin Eli | 10% Owner | 10,000,000 | Oct 5, 2022 | 0 |
| Casdin Partners Master Fund, L.P. | 10% Owner | 10,000,000 | Oct 5, 2022 | 0 |
| Murphy Amanda Louise | Chief Financial Officer | 0 | Mar 29, 2022 | 0 |
| Thompson J Stark PhD | Director | – | Aug 11, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 (view filing) | Dec 26 | 4 days | Johnston John JosephDirector | SSale | −3.00K | $4.01 | −$12.0K | −2.1%141.9K after | 10b5-1 |
| Jan 14, 2025 (view filing) | Jan 13 | 1 day | Sandoval David I.GENERAL COUNSEL | SSale | −4.47K | $4.54 | −$20.3K | −9.7%41.4K after | |
| Jan 29, 2025 (view filing) | Jan 27 | 2 days | Johnston John JosephDirector | SSale | −3.00K | $4.65 | −$13.9K | −2.1%141.9K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Swirsky Douglas JCHIEF FINANCIAL OFFICER | SSale | −6.94K | $3.18 | −$22.1K | −5.8%111.8K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Sandoval David I.GENERAL COUNSEL | SSale | −353 | $3.18 | −$1.12K | −0.5%64.2K after | |
| Mar 20, 2025 (view filing) | Mar 18 | 2 days | Soleymannezhad AliChief Commercial Officer | SSale | −1.21K | $3.18 | −$3.85K | −2.0%59.4K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Brooke William WDirector | PPurchase | +50.0K | $1.29 | +$64.5K | +49.6%150.9K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Douglas RichardDirector | PPurchase | +80.0K | $1.39 | +$111.2K | +53.1%230.6K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Erck Stanley CDirector | PPurchase | +100.0K | $1.37 | +$137.0K | +33.5%398.3K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Masoud MaherPresident and CEO | PPurchase | +75.0K | $1.37 | +$102.8K | +75.0%175.0K after | |
| Aug 13, 2025 (view filing) | Aug 13 | Same day | Swirsky Douglas JCHIEF FINANCIAL OFFICER | PPurchase | +50.0K | $1.29 | +$64.5K | +44.7%161.8K after | |
| Aug 27, 2025 (view filing) | Jun 25 | 63 daysLate | Hemrajani RekhaDirector | SSale | −10.7K | $2.09 | −$22.3K | −21.1%39.9K after | 10b5-1 |
| Mar 19, 2026 (view filing) | Mar 17 | 2 days | Swirsky Douglas JCHIEF FINANCIAL OFFICER | SSale | −10.1K | $0.82 | −$8.32K | −6.3%151.7K after |